Citigroup cuts BridgeBio Pharma target price to $91 from $94
BBIO•Citigroup cut its target price for BridgeBio Pharma to $91 from $94.
Related News
B2Gold Corp.: Raymond James cuts target price to $7.25 from $7.50
BTG•
Citizens Financial: Raymond James cuts target price to $76 from $77
CFG•
FirstEnergy Pennsylvania Electric extends exchange offer for notes due 2028 and 2031
FE•
Analysts revise targets for Analog Devices, IBM and Qualcomm
ADI•
EyePoint announces strategic prioritization
EYPT•